SAT0171 Abp 501 biosmilar to adalimumab: final safety, immunogenicity, and efficacy results from an open-label extension study

Abstract

BackgroundABP 501 has been approved by the US FDA as the first biosimilar to the fully human recombinant monoclonal antibody, adalimumab. Totality of evidence to date suggests that ABP 501...